ClinicalTrials.gg
RecruitingNCT06911229Updated Jul 15, 2026

Neurophysiology of Locomotor Adaptation and Freezing of Gait in Parkinson's Disease

An interventional study of Deep Brain Stimulation (DBS) in Parkinson Disease, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by University of Florida · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Parkinson Disease by University of Florida — 5 open to participants now, 6 under way, none of them phase 3. Parkinson Disease · University of Florida.

Planned enrollment
8th of 33
60 · median 35
Started
2025
with 1 other
No phase
25 of 41
5 open now
Registered
37th of 41
by date

Among the 41 studies in Parkinson Disease by University of Florida, this one is the 8th largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2025, is one of 25 with no phase, and was the 37th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 41 studies in Parkinson Disease by University of Florida are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Parkinson Disease by University of Florida, or all of them as a file.
02

Study summary

Locomotor adaptation will be studied using an established split-belt treadmill paradigm, consisting of baseline (1:1 speed ratio), split-belt adaptation (2:1) and post-adaptation (1:1) walking. Split-belt walking will be performed under DBS ON and DBS OFF conditions, while off-medication.

Read the detailed description

We will test the hypotheses that DBS can facilitate split-belt walking adaptation with DBS ON compared with DBS OFF.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Freezing of gait
  • deep brain stimulation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • consensus diagnosis of idiopathic PD by fellowship trained movement disorders neurologists at the Normal Fixel Institute of Neurological Diseases;
  • chronically stable DBS, defined as having had DBS for at least 6 months in duration with optimized DBS settings;
  • Age between 18 - 80 years old per the FDA data sheet for PD DBS;
  • no dementia according to the clinical diagnostic criteria for PD dementia;
  • ambulatory without the use of walking aids, or another person's assistance.

Exclusion criteria

Exclusion Criteria:

  • other previous neurological surgery;
  • suspicion of other neurologic diagnoses such as atypical parkinsonism, or Alzheimer's disease.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    DBS ON

    DBS will be turned on

    Device: Deep Brain Stimulation (DBS)

  • No intervention
    DBS OFF

    DBS will be turned off

Interventions

  • DeviceDeep Brain Stimulation (DBS)

    Patients will receive DBS in the clinically-optimized setting.

06

What researchers measure

Primary outcomes

  1. Step length rate of adaptation

    The rate of adaptation in step length asymmetry is estimated by fitting an exponential decay function to step length asymmetry over the first 100 strides in adaptation.

    Time frame: 1 hour

  2. Step length magnitude of adaptation

    The magnitude of adaptation in step length asymmetry is calculated as the mean difference in step length asymmetry between early and late adaptation.

    Time frame: 1 hour

  3. Step length after-effects

    The after-effect in step length asymmetry is calculated as the mean difference in step length asymmetry between baseline and early post-adaptation.

    Time frame: 1 hour

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jul 2027, 21 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 21 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 4, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06911229
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Oct 1, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Julia Choi, Ph.D.
Contact
juliachoi@ufl.edu
3522941720

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion